Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine

Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days and 15.5% at 90-daysSafety profile consistent with standard of care with no significant difference in adverse eventsTigris trial results to be presented at the Society of Critical Care Medicine (“SCCM”) in Chicago, Ill. on March 24, 2026  TORONTO ...